NORDICC Trial Summary: Colonoscopy for Colorectal Cancer Screening

nordicc trial colonoscopy

2022 NORDICC TRIAL Effect of colonoscopy screening on risks of colorectal cancer and related death pragmatic, multicenter, randomized controlled trial Objective: To investigate the effects of population-based colonoscopy screening on the risks of colorectal cancer and related death at 10 years 84,585 patients Inclusion criteria: Presumptively healthy men and women 55 to 64 years of age drawn from population registries in Poland, Norway, Sweden, and the Netherlands X VS Invited group: Single screening colonoscopy (n=28,220) Usual-care group (n=56,365) PRIMARY OUTCOME 0.98 Risk of colorectal cancer at 10 years % RR 0.82; 95% CI, 0.70 to 0.93 1.20 0.28 Risk of death from colorectal cancer % RR 0.90; 95% CI, 0.64 to 1.16 0.31 SECONDARY OUTCOME 11.03 Death from any cause at 10 year % RR 0.99; 95% CI, 0.96 to 1.04 11.04 Conclusion: In this randomized trial, the risk of colorectal cancer at 10 years was lower among participants who were invited to undergo screen’ ing colonoscopy than among those who were assigned to no screening. M Bretthauer et al. NEJM 2022; 387:1547-1556